Premium
Rationally Designed Self‐Assembling Nanoparticles to Overcome Mucus and Epithelium Transport Barriers for Oral Vaccines against Helicobacter pylori
Author(s) -
Zhang Yuandong,
Li Haibo,
Wang Qin,
Hao Xinyan,
Li Hanmei,
Sun Heqiang,
Han Lu,
Zhang Zhirong,
Zou Quanming,
Sun Xun
Publication year - 2018
Publication title -
advanced functional materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.069
H-Index - 322
eISSN - 1616-3028
pISSN - 1616-301X
DOI - 10.1002/adfm.201802675
Subject(s) - helicobacter pylori , mucus , paracellular transport , immune system , microbiology and biotechnology , medicine , immunology , biology , ecology , genetics , membrane , permeability (electromagnetism)
Helicobacter pylori infection is strongly associated with chronic gastritis, peptic ulcers, and gastric cancer. Antibiotic resistance in H. pylori is an increasingly serious threat to global public health. Although oral vaccination is considered to be a promising strategy for protection against H. pylori infection, the poor efficacy of oral vaccines remains a major challenge due to their poor ability to penetrate mucus and cross transepithelial absorption barriers. This study reports the development of a well‐designed nanoparticle that is electrostatically self‐assembled with antigen and cell‐penetrating peptide (CPP), and then coated with a “mucus‐inert” PEG derivative. The nanoparticles have hydrophilic and slightly negative surface properties, which confers excellent mucus‐penetrating ability. Studies demonstrate that the self‐assembled PEG derivatives gradually dissociate from the nanoparticles in mucus, exposing the CPP‐rich cores that are efficiently transepithelial transported via intracellular and paracellular pathways. Nanoparticles containing recombination urease subunit B, a candidate vaccine against H. pylori , significantly enhance systemic and mucosal antibody levels in mice, and these immune responses protect the animals from H. pylori challenge. These results suggest that the CPP‐rich PEGylated nanoparticles may be a powerful platform for building an oral vaccine to protect against gastrointestinal infection by recalcitrant H. pylori or/and other pathogenic microorganisms.